semaglutide alzheimer clinical trial Weight-loss drug does not slow Alzheimer's disease, two trials find Blockbuster GLP-1 Diabetes and Weight

Severe multisystem symptoms require specialist evaluation Seizures, metabolic strokes, severe weakness, cardiomyopathy, developmental regression, exercise-induced rhabdomyolysis, lactic acidosis, major hearing or vision loss and strong maternal inheritance patterns may require neurological, metabolic or genetic evaluation

10.1038/nm1202-793 37 CarrollT

What About TMAO And Heart Safety

Quantification of erythroblast populations at different differentiation stages using surface markers (bottom): Ter119 and CD44, and FSC (size)

Higher doses (4.5 mg) were evaluated but discontinued due to excessive gastrointestinal side effects without proportional benefits[7]

Taken together, the two trials, which were reported in a poster discussion session at the annual meeting of the American Society of Clinical Oncology, provide yet another cautionary lesson on the complexity of combining conventional and complementary therapies